McGuire Investment Group LLC bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating ) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 35,081 shares of the company’s stock, valued at approximately $1,224,000.
→ Bank accounts: Frozen! (From Weiss Ratings)
A number of other hedge funds and other institutional investors have also bought and sold stakes in the business. Equis Capital Management Inc. boosted its stake in Intellia Therapeutics by 5.1% in the third quarter. Equis Capital Management Inc. now owns 4,345 shares of the company’s stock valued at $243,000 after buying an additional 210 shares during the period. Xponance Inc. boosted its stake in Intellia Therapeutics by 5.2% in the third quarter. Xponance Inc. now owns 4,250 shares of the company’s stock valued at $238,000 after purchasing an additional 210 shares during the period. Amalgamated Bank boosted its stake in Intellia Therapeutics by 2.0% in the third quarter. Amalgamated Bank now owns 11,352 shares of the company’s stock valued at $635,000 after purchasing an additional 222 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intellia Therapeutics by 1.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,777 shares of the company’s stock valued at $883,000 after buying an additional 247 shares during the period. Finally, Cubist Systematic Strategies LLC raised its stake in Intellia Therapeutics by 0.3% in the third quarter. Cubist Systematic Strategies LLC now owns 87,367 shares of the company’s stock valued at $4,889,000 after buying an additional 279 shares during the period. Hedge funds and other institutional investors own 85.61% of the company’s shares.
Insiders place their bets
In other Intellia Therapeutics news, CFO Glenn Goddard sold 2,427 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $90,308.67. Following the completion of the sale, the chief financial officer now owns 15,404 shares of the company’s stock, valued at $573,182.84. The sale was disclosed in a filing with the SEC, which is available via this hyperlink. In other news, CFO Glenn Goddard sold 2,427 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $90,308.67. Following the completion of the transaction, the chief financial officer now directly owns 15,404 shares in the company, valued at $573,182.84. The sale was disclosed in a document filed with the SEC, which is available on the SEC’s website. Also, CEO John M. Leonard sold 6,673 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $248,302.33. Following the completion of the transaction, the chief executive officer now owns 766,825 shares of the company’s stock, valued at $28,533,558.25. Disclosure of this sale can be found here. Over the last 90 days, insiders have sold 11,608 shares of company stock worth $431,934. 3.90% of shares are currently owned by corporate insiders.
The Wall Street analyst weighs in
A number of analysts have weighed in on the company. Citigroup raised Intellia Therapeutics from a “sell” rating to a “neutral” rating and cut their target price for the stock from $48.00 to $39.00 in a research note on Tuesday, January 24th. Credit Suisse Group reduced their target price on Intellia Therapeutics from $88.00 to $76.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. Chardan Capital cut their target price on Intellia Therapeutics from $129.00 to $111.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Raymond James reduced their target price on Intellia Therapeutics from $124.00 to $94.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. Finally, SVB Leerink reduced their target price on Intellia Therapeutics from $86.00 to $84.00 and set an “outperform” rating on the stock in a research note on Monday, January 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.25, according to MarketBeat.com.
Price performance of Intellia Therapeutics
NASDAQ NTLA traded down $0.79 during trading on Friday, reaching $39.76. The company’s stock had a trading volume of 301,452 shares, compared to its average volume of 1,185,397. The business’s 50-day Simple Moving Average is $39.65, and the 200-day Simple Moving Average is $46.55. Intellia Therapeutics, Inc. has a fifty-two week low of $32.44 and a fifty-two week high of $78.58.
Intellia Therapeutics (NASDAQ:NTLA – Get Rating ) last posted its quarterly earnings results on Thursday, February 23rd. The company reported ($1.40) earnings per share for the quarter, hitting the consensus estimate of ($1.40). The business had revenue of $13.60 million during the quarter, compared to the consensus estimate of $10.71 million. Intellia Therapeutics had a negative return on equity of 48.70% and a negative net margin of 909.78%. The company’s quarterly revenue was up 5.4% year over year. In the same quarter last year, the company earned ($1.09) earnings per share. As a group, stock analysts expect Intellia Therapeutics, Inc. to post -5.81 EPS for the current fiscal year.
About Intellia Therapeutics
(Get Rating)
Intellia Therapeutics, Inc is a clinical-stage genome editing company engaged in the development of therapeutics using the CRISPR/Cas9 system. His CRISPR/Cas9 system is transforming medicine by producing therapeutics that permanently edit and/or correct disease-related genes in the human body with a single course of treatment, and creating engineered cells that can treat oncological and immunological diseases.
Read more
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Intellia Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks top analysts are quietly whispering to their clients to buy now before the broader market takes a nosedive … and Intellia Therapeutics wasn’t on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, the top rating analysts consider these five stocks to be better buys.
Check out the five stocks here
